Sanofi acquiring AblynxBriefly after Belgian nanobody maker Ablynx rejected a €2.3bn take-over bid of Novo, its board accepted a €3.9bn tender of its R&D partner Sanofi. It’s the second large take-over of Sanofi this … more ➔
EMA recommends seven new drugs for market The European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) greenlighted seven medicines for approval at its January 2018 meeting, including one orphan medicine, and one biosimilar. more ➔
Bacterium blocks dengue and Zika virus tra... Scientists at the University of Glasgow have found a bacterial strain which blocks dengue and Zika virus transmission from mosquitoes. more ➔
Novartis in US$170m licence deal with Spar...Novartis AG has strengthened its ophtalmology portfolio by acquiring a licence for Spark Therapeutics voretigene neparvovec (Luxturna), an FDA-approved gene therapy that corrects mutations in RPE65, … more ➔
Protein keeps breast cancer metastases at...Spanish researchers have identified a protein that keeps breast cancer stem cell in a dormant state preventing them from forming metastases. A German team found an endothelial receptor protein that prevents … more ➔
Seventure Partners joins US$35m round into...Venture capital firm Seventure Partners has joined a US$35m Series B Round in Digital Nutrition Platform Zipongo. The US$9m invested into the Californian company comes from Seventures €160m Health … more ➔
Sanofi takes over Bioverativ in US$11.8bn...Seven years after the acquisition of Genzyme, French drug major Sanofi has added another orphan drug player to its portfolio. The company agreed with the management of US blood disorder expert Bioverativ … more ➔
Novel blood test detects eight cancersItalian, US and Australian researchers have used a blood screening test to detect cancer in patients with 8 different cancers whose tumors had not yet spread. Its sensivity is among the best performances … more ➔
Government funds TxCells CAR-Treg therap...French immunotherapy company TxCell received a €1.2m funding from the French governemt agency Bpifrance to develop its genetically engineered regulatory T cells (Tregs). more ➔
Da Volterras DAV132 helps fighting AMR c...French microbiota specialist Da Volterra announced that its colon-targeted adsorbent, DAV132, can protect the intestinal microbiota from disruption caused by antibiotics. more ➔
